Ph 1/2 Study to Evaluate Safety & Tolerability of FMC-242 Alone and in Combination in Adults With Advanced Solid Tumors (ENGAGE)

November 11, 2026 updated by: Frontier Medicines Corporation

A Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of FMC-242 as a Single Agent and in Combination in Participants With Advanced Solid Tumors

The goal of this clinical trial is to learn if treatment in adults with select solid tumors with FMC-242 alone and in combinations with other cancer drugs is safe and effective. The main questions it aims to answer are:

Is treatment with FMC-242 alone safe and tolerable and at what dose? Is treatment with FMC-242 combined other cancer drugs safe and tolerable and at what doses?

Participants will need to come to the clinic to have the following:

  • Physical exams to see if there are any side effects
  • Standard lab tests to observe blood counts and other values
  • ECGs to measure heart signals
  • Blood drawn to measure how the drugs are being metabolized
  • Imaging such as CT scans to monitor if the cancer is growing or not

Study Overview

Detailed Description

This is a first-in-human, Phase 1/2, open-label, multi-center dose escalation and expansion study to evaluate the safety, tolerability, PK, and anti-tumor activity of FMC-242 monotherapy and in combination in participants with locally advanced or metastatic solid tumors. FMC-242 is in a new class of drugs called PI3Kα:RAS breakers. The combination escalation cohorts may enroll while the monotherapy portion is still determining MTD/recommended dose for expansion (RDE).

This study is being conducted in two phases:

Phase 1 Dose Escalation: to determine the MTD and/or preliminary RP2D(s) and dosing regimen of FMC-242 monotherapy and in combination.

Phase 2 Cohort Expansion: to evaluate the efficacy and safety of FMC-242 at the RP2D(s) as a monotherapy and in combination in disease-specific cohorts.

After consenting to participate, participants will complete screening assessments during a Screening Period. Eligible participants will receive FMC-242 orally, at approximately the same time each day.

Depending on the tumor type, participants in combination cohorts will also receive the addition of another cancer drug administered per the local prescribing information/investigational labeling.

Study Type

Interventional

Enrollment (Estimated)

282

Phase

  • Phase 2
  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Males and females of age ≥ 18 years at the time of signing the informed consent document.
  • No known downstream mutations in the AKT or RAS pathway
  • Measurable disease per RECIST v1.1.
  • Documented disease progression on, or disease recurrence after at least 1 line of standard of care (SoC) systemic treatment, including approved targeted therapy for patients with actionable mutations, or, in the opinion of the Investigator, would not be able to tolerate SoC therapy, or refused SoC therapy.
  • Eastern Cooperative Oncology Group performance status 0-1.
  • Adequate hematological, renal, and hepatic function.
  • In Phase 1 only, must be willing to provide an on treatment tumor biopsy provided it is safe and medically feasible.
  • Women and men of child-bearing potential must agree to use highly effective contraceptive methods.
  • Willing and able to adhere to the study visit schedule and other protocol requirements.
  • Has an archival tissue for retrospective confirmatory testing, unless discussed with the study Medical Monitor.

Exclusion Criteria:

  • Prior use of a PI3Kα:RAS breaker (e.g., BBO-10203, VVD-159642).
  • Prior use of a RAS inhibitor (either pan-RASi or isoform-specific)
  • Received any systemic anti-cancer therapy or investigational therapy within 21 days or 5 half-lives, whichever is shorter, prior to the first dose of study drug.
  • Received radiation within 14 days prior to the first dose of study drug.
  • Clinically significant toxicity resulting from prior cancer therapies that have not returned to baseline or ≤ Grade 1
  • Known, uncontrolled central nervous system (CNS) metastases.
  • History of myocardial infarction or unstable angina within 6 months prior to enrollment, or clinically significant cardiac disease
  • Prior malignancy, requiring treatment or intervention, within the previous 3 years of study drug dosing, except for appropriately treated local malignancies that have been apparently cured, such as basal or squamous cell skin cancer, which are allowed.
  • Pregnant or breastfeeding.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Sequential Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: FMC-242 Monotherapy

FMC-242 alone

PI3Kα:RAS breaker

Experimental: Combination Cohort A

FMC-242 in combination with trastuzumab

PI3Kα:RAS breaker

HER2 targeting agent

Other Names:
  • Herceptin
Experimental: Combination Cohort B

FMC-242 in combination with fulvestrant

PI3Kα:RAS breaker

selective estrogen receptor degrader

Other Names:
  • Faslodex
Experimental: Combination Cohort C

FMC-242 in combination with a Pan (K)RAS inhibitor

PI3Kα:RAS breaker

Pan (K)RAS inhibitor

Experimental: Combination Cohort D

FMC-242 in combination with FMC-376

PI3Kα:RAS breaker

KRAS G12C inhibitor (experimental)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Phase 1 and Phase 2: Adverse Events
Time Frame: Approximately 24 months

Number and grade of adverse events (AEs) with FMC-242 alone and in each of the combinations using CTCAE v 6.0

Approximately 24 months
Phase 1 : Dose Limiting Toxicities
Time Frame: Up to 21 or 28 days

Number of dose limiting toxicities (DLTs) with FMC-242 alone and in each of the combinations

Up to 21 or 28 days
Phase 2: Overall Response Rate
Time Frame: Approximately 24 months

Assess the overall response rate (ORR) using RECIST 1.1 in participants treated with FMC-242 alone and in each of the combinations

Approximately 24 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Phase 1: Assess anti-tumor activity
Time Frame: Approximately 24 months

To assess preliminary anti-tumor activity of FMC-242 alone and in combinations using RECIST v1.1

Approximately 24 months
Phase 1: FMC-242 Maximum observed plasma concentration
Time Frame: 6 weeks

Measure the maximum observed plasma concentration (Cmax) for FMC-242

6 weeks
Phase 1: FMC-242 time to maximum observed plasma concentration
Time Frame: 6 weeks

Measure time to maximum observed plasma concentration (Tmax) for FMC-242

6 weeks
Phase 1: FMC-242 trough observed concentration
Time Frame: 6 weeks

Measure trough observed concentration (Cmin) for FMC-242

6 weeks
Phase 1: Area under the concentration-time curve from time zero to time of last quantifiable concentration or in one dosing interval
Time Frame: 6 weeks

Measure area under the concentration-time curve from time zero to time of last quantifiable concentration or in one dosing interval (AUC0-t, AUCtau) for FMC-242

6 weeks
Phase 1: Terminal half-life
Time Frame: 6 weeks

Measure the terminal half-life (t1/2) for FMC-242

6 weeks
Phase 1: Apparent clearance
Time Frame: 6 weeks

Determine apparent the clearance (Cl/F) for FMC-242

6 weeks
Phase 1: Determine the volume of distribution
Time Frame: 6 weeks

Determine volume of distribution (Vd/F) for FMC-242

6 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Aaron (Ron) Weitzman, MD, Frontier Medicines

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

December 1, 2026

Primary Completion (Estimated)

January 1, 2029

Study Completion (Estimated)

January 1, 2030

Study Registration Dates

First Submitted

November 11, 2026

First Submitted That Met QC Criteria

November 11, 2026

First Posted (Actual)

November 18, 2026

Study Record Updates

Last Update Posted (Actual)

November 18, 2026

Last Update Submitted That Met QC Criteria

November 11, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Aggregate study data will be shared at the end of the study.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe